Abstract: A decentralized investment fund operates according to consensus code on a shared ledger and raises capital by issuing ownership tokens on the shared ledger. The decentralized investment fund may hold digital assets in the consensus code and distribute profits to the token owners according to each owner's dividend preference. A token owner's dividend preference can include digital assets tracked by a different shared ledger, stabletoken digital assets pegged to the value of a digital asset, and cross-chain digital asset swaps. Token issuance may include a proof of accreditation requirement based on cryptographic proof on a shared ledger. The decentralized investment fund may distribute fund documents to the token holders by encrypting the document, first with a symmetric key common to all token holders, and second with an asymmetric key unique to each token holders and based on the token's holder's known public address on the shared ledger.

Abstract: A decentralized investment fund operates according to consensus code on a shared ledger and raises capital by issuing ownership tokens on the shared ledger. The decentralized investment fund may hold digital assets in the consensus code and distribute profits to the token owners according to each owner's dividend preference. A token owner's dividend preference can include digital assets tracked by a different shared ledger, stabletoken digital assets pegged to the value of a digital asset, and cross-chain digital asset swaps. Token issuance may include a proof of accreditation requirement based on cryptographic proof on a shared ledger. The decentralized investment fund may distribute fund documents to the token holders by encrypting the document, first with a symmetric key common to all token holders, and second with an asymmetric key unique to each token holders and based on the token's holder's known public address on the shared ledger.

Abstract: A decentralized investment fund operates according to consensus code on a shared ledger and raises capital by issuing ownership tokens on the shared ledger. The decentralized investment fund may hold digital assets in the consensus code and distribute profits to the token owners according to each owner's dividend preference. A token owner's dividend preference can include digital assets tracked by a different shared ledger, stabletoken digital assets pegged to the value of a digital asset, and cross-chain digital asset swaps. Token issuance may include a proof of accreditation requirement based on cryptographic proof on a shared ledger. The decentralized investment fund may distribute fund documents to the token holders by encrypting the document, first with a symmetric key common to all token holders, and second with an asymmetric key unique to each token holders and based on the token's holder's known public address on the shared ledger.

Abstract: A decentralized investment fund operates according to consensus code on a shared ledger and raises capital by issuing ownership tokens on the shared ledger. The decentralized investment fund may hold digital assets in the consensus code and distribute profits to the token owners according to each owner's dividend preference. A token owner's dividend preference can include digital assets tracked by a different shared ledger, stabletoken digital assets pegged to the value of a digital asset, and cross-chain digital asset swaps. Token issuance may include a proof of accreditation requirement based on cryptographic proof on a shared ledger. The decentralized investment fund may distribute fund documents to the token holders by encrypting the document, first with a symmetric key common to all token holders, and second with an asymmetric key unique to each token holders and based on the token's holder's known public address on the shared ledger.

Abstract: Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR).

Abstract: An apparatus for guiding an anti-rotation key installation tool includes at least one magnet mounting member. A tool positioning member is coupled to the magnet mounting member and has a first end and a second end. An installation tool positioning channel extends from the first end to the second end of the tool positioning member and has an opening at the first end of the tool positioning member for accepting a portion of the anti-rotation key installation tool. At least one mechanically switchable frame securing magnet assembly is mounted to the at least one magnet mounting member for releasably securing the apparatus to an outer surface of a tubular connection.

Abstract: Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR).

Abstract: The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Abstract: An apparatus for guiding an anti-rotation key installation tool includes at least one magnet mounting member. A tool positioning member is coupled to the magnet mounting member and has a first end and a second end. An installation tool positioning channel extends from the first end to the second end of the tool positioning member and has an opening at the first end of the tool positioning member for accepting a portion of the anti-rotation key installation tool. At least one mechanically switchable frame securing magnet assembly is mounted to the at least one magnet mounting member for releasably securing the apparatus to an outer surface of a tubular connection.

Abstract: Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.

Abstract: Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR).

Abstract: Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.

Abstract: The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.

Abstract: The present invention relates to compositions and processes of using perfluoropolyether to maintain or improve the oil return, lubrication, cooling capacity or energy efficiency of the refrigeration, air conditioning and heat transfer system.

Abstract: The present invention relates to compositions and processes of using perfluoropolyether to maintain or improve the oil return, lubrication, cooling capacity, or energy efficiency of a refrigeration, air conditioning or heat transfer system.

Abstract: The present invention relates to compositions and processes of using perfluoropolyether to maintain or improve the oil return, lubrication, or energy efficiency of the refrigeration, air conditioning and heat transfer system.

Abstract: A composite battery set, including a metal-ceramic ruthenium-oxide ultracapacitor and a secondary lithium-ion battery, is provided. The composite battery set is electrically connected to an electrical device, which cuts down the total impedance by the metal-ceramic ruthenium-oxide ultracapacitor to increase the output power and the current. The composite battery set is also able to react a pulse rise time less than 5 ms, to speed up the signal react time of the electronic device. And the composite battery set further includes a protective circuit module (PCM) to protect the secondary lithium-ion battery so as to extend the service life and lifespan.

Abstract: An interlock for a vehicle platform lift meets the Federal Motor Vehicle Safety Standards (FMVSS 403) effective in late 2004 with minimum modification of vehicle electronic control arrangements. The interlock prevents forward and rearward mobility of vehicles unless the platform lift is stowed. The interlock operates to prevent accidental release but does not affect vehicle movement when the platform lift is stowed. Operation of the lift is allowed by placing the transmission in park or by placing the transmission in neutral and actuating the parking brake. A vehicle body computer controls operation when the vehicle is running. A bypass enable relay allows use when the vehicle's engine is not running.

Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.